Archived Facts

The price of Peregrine Pharmaceuticals Inc. stock collapsed Monday after the cancer drug developer told analysts they should not rely on recently disclosed data about its lead product, the potential lung cancer treatment bavituximab.

Popular Posts:

Related Posts:

  • No Related Posts

Leave a Reply